Work

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.6_suppl.tps257

Authors: Kim N. Chi, Dana E. Rathkopf, Gerhardt Attard, Matthew Raymond Smith, Eleni Efstathiou, David Olmos, Eric Jay Small, Ji Youl Lee, Paul R. Sieber, Curtis Dunshee, Deborah S. Ricci, Jason S. Simon, Xin Zhao, Nishi Kothari, Shinta Cheng, Shahneen Kaur Sandhu

Institutions: Vancouver Prostate Centre, Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Royal Marsden Hospital, Massachusetts General Hospital, Spanish National Cancer Research Centre, UCSF Helen Diller Family Comprehensive Cancer Center, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Bristol-Myers Squibb (United States), Janssen Research & Development (United States), The University of Melbourne, Peter MacCallum Cancer Centre

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Janssen Research and Development

OpenAlex ID: W4248868233

Cites:

Cited by: 3

Related to: 10